

FROM HYPERTENSION TO CARDIOVASCULAR DISEASE (CVD) 2026:  
ADHERENCE, ARTIFICIAL INTELLIGENCE (AI) AND MENOPAUSE

# CME LIVE WEBINAR

## From Hypertension to CVD and the role of AI

**19 June 2026**  
from 14.00 to 15.00 CEST

Pre-webinar interview: 26 May 2026  
Post-webinar infographic: 1 July 2026

**MeδEA**  
Medical Education Academy



# From Hypertension to Cardiovascular Disease and the role of Artificial Intelligence (AI)

**Pre-webinar interview: 26 May 2026**

**Live webinar: 19 June 2026 from 14.00 to 15.00 CEST**

**Post-webinar infographic: 1 July 2026**

## Overview

High blood pressure (BP)/hypertension is associated with the strongest evidence for causation of CVD [Fuchs, 2020]. Indeed, trials over time have demonstrated the potential CVD benefits associated with BP-lowering treatments at lower and lower pre-treatment BP measurements and at any stage of hypertension duration [McCarthy, 2024; Pfeffer, 2016; Ling 2024]. Recent artificial intelligence (AI) advances in CV medicine and care offer potential enhancements in diagnosis, accelerate making clinical decisions, treatment, clinical outcomes, remote patient monitoring, patient phenotyping and assessing the risk of complications [Elias, 2024; Belenkov, 2025] as well as enhancing risk prediction [Teshale, 2024; Tremamunno, 2025; Chaparala, 2025; Gonzalez, 2024]. To-date, AI innovations span automating measurements, enhancing image quality/tomographic image analysis as well as wearable devices, echocardiography, angiography and genetics [Ose, 2024] at a greater accuracy not previously achieved. AI shows great promise in enhancing CVD care through more accurate and efficient approaches [Bota, 2024]. However, the unique characteristics offered by AI require rigorous validation in terms of training, real-world efficacy, equity concerns and long-term reliability and future efforts should focus on the impact of AI technologies on patient outcomes and ethical challenges [Guha, 2025; Shaikh, 2025].

## Learning Objectives

**At the end of the activity, learners should be able to:**

- Appreciate the factors to consider when treating hypertension and the impact they have on the development of CVD
- Be familiar with the latest understanding for predicting the development of CVD from hypertension
- Understand the role of AI in the risk prediction, detection and management of CVD and its ethical considerations and implications

## Target Audience

Clinicians (including cardiologists, internists, and general practitioners), nurse practitioners and other HCPs who diagnose and manage patients with CVD and hypertension.

## Language

English with simultaneous translation into Russian and Chinese.

# Continuing Medical Education

The From Hypertension to Cardiovascular Disease and the role of Artificial Intelligence (AI) programme will be submitted for CME accreditation from the European Accreditation Council for Continuing Medical Education (EACCME), and for Continuing Professional Development (CPD) credits.

## Faculty



**Stefano Taddei**  
Full Professor of Internal Medicine  
Director of the Hypertension Unit  
Department of Clinical and Experimental Medicine  
University of Pisa  
Pisa, Italy



**Gianluigi Savarese**  
Associate Professor of Cardiology  
Department of Medicine  
Karolinska Institute & Consultant in Heart Failure  
Karolinska University Hospital  
Stockholm, Sweden



**Rhian M. Touyz**  
Executive Director and Chief Scientific Officer  
Research Institute  
McGill University Health Centre  
Montreal (Quebec), Canada

## Programme

**CLICK HERE**

to view info  
and agenda



OR SCAN



## Registration

**CLICK HERE**

to register  
FOR FREE



OR SCAN



## CME Provider

**MedEA Medical Education Academy**

Senior Educational Programme Director: Flaminia Masprone

T 39 02 8295 865

[info@medeaacademy.com](mailto:info@medeaacademy.com)

This educational programme is made possible thanks to an independent educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.